LONDON, Nov. 10, 2016 /PRNewswire/-- Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announcesthat Christian Hogg, Chief Executive Officer, will present at the upcoming Deutsche Bank American Depositary Receipt ("ADR") Virtual Investor Conference ("dbVIC").
Participation is free of charge. It is recommended that investors pre-register to save time.
dbVIC offers investors access to global companies with ADR programs in a live, interactive online event. Investors are invited to ask international companies their questions real-time and to download a company's information in their "virtual trade booth", in the Exhibits section.
Attendees not able to join the event live during the conference will have access to an on-demand archive, which will be available for 90 days.
Recent Company Highlights
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward looking statements reflect Chi-Med's current expectations regarding future events and can be identified by words like: "will," "expects," "believes" or similar terms, or by express or implied discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Unless the context requires otherwise, references in this press release to the "Group," the "Company," "Chi-Med," "Chi-Med Group," "we," "us" and "our" refer to Chi-Med and its consolidated subsidiaries and joint ventures unless otherwise stated or indicated by context.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chi-med-to-present-at-the-deutsche-bank-adr-virtual-investor-conference-on-wednesday-november-16-2016-300360493.html
SOURCE China MediTech Limited (“Chi-Med”)
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All